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ABSTRACT: Background: GBA mutations are a
common risk factor for Parkinson’s disease (PD). A
recent study has suggested that GBA haplotypes,
identified by intronic variants, can affect age at diag-
nosis of PD.
Objectives: In this study, we assess this hypothesis
using long reads across a large cohort and the pub-
licly available Accelerating Medicines Partnership–
Parkinson’s Disease (AMP-PD) cohort.
Methods: We recruited a PD cohort through the
Remote Assessment of Parkinsonism Supporting
Ongoing Development of Interventions in Gaucher
Disease study (RAPSODI) and sequenced GBA using
Oxford Nanopore technology. Genetic and clinical
data on the full AMP-PD cohort were obtained from
the online portal of the consortium.
Results: A total of 1417 participants were analyzed.
There was no significant difference in age at PD diagno-
sis between the two main haplotypes of the GBA gene.
Conclusions: GBA haplotypes do not affect age at
diagnosis of PD in the two independent cohorts studied.
© 2021 The Authors. Movement Disorders published by
Wiley Periodicals LLC on behalf of International
Parkinson and Movement Disorder Society
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Mutations in the GBA gene are an important risk
factor for the development of Parkinson’s disease
(PD).1 The prevalence of GBA mutations in PD varies
according to the population studied and whether the
analysis includes all coding variants or only the most
common; in general it ranges between 5% and 10% of
sporadic PD cases.2 The Ashkenazi Jewish population
is an exception, with a prevalence of GBA mutations as
high as 30% in sporadic PD cases.3 The lifetime risk of
development of PD in exonic GBA mutation carriers is
estimated at 5% to 30%,4 and it is not clear what fac-
tors contribute to this incomplete penetrance. More-
over, reduced activity of the enzyme encoded by GBA,
glucocerebrosidase, is observed in PD brains without
coding GBA mutations.5
A recent study explored the hypothesis that intronic vari-
ants in the GBA gene might contribute to the risk of PD.6
Deep intronic variants are not commonly regarded as path-
ogenic as they do not result in amino acid changes in pro-
teins. Nonetheless, some deep intronic variants have been
linked directly to genetic disorders, such as Gaucher dis-
ease.7,8 Two common haplotypes were identified, differen-
tiated by three intronic single nucleotide polymorphisms in
GBA. These correspond to the previously reported 1.1+
and 1.1− haplotypes.9,10 These haplotypes had a signifi-
cant effect on age at onset and age at diagnosis of PD.
In this article, we analyzed our cohort of patients with
PD and the publicly available Accelerating Medicines
Partnership–Parkinson’s Disease (AMP-PD) cohort to try
to replicate these findings.
Patients and Methods
Recruitment of Participants
Patients with PD were recruited through the Remote
Assessment of Parkinsonism Supporting Ongoing
Development of Interventions in Gaucher Disease study
(RAPSODI) (http://rapsodistudy.com) an online cohort
study that recruits and genotypes people with PD
through a dedicated portal (http://pdfrontline.com).
After signing an online consent form, participants were
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assessed remotely, and demographic and clinical infor-
mation was recorded. Participants provided saliva
DNA for analysis. The London Queen Square Research
Ethics Committee approved the project.
DNA Extraction and Sequencing
Saliva was collected using the Oragene DNA OG-500
kit (DNA Genotek), and DNA was extracted according to
the manufacturer’s protocol. Sequencing of long GBA
amplicons was carried out using Oxford Nanopore Tech-
nologies as described previously.11 Sequencing data were
generated using MinKNOW, basecalled with Guppy (both
available via the Nanopore community site; https://
community.nanoporetech.com), and aligned to hg38 with
NGMLR.12 Variants were called using Clair13 and phased
with Whatshap.14 Haplotypes were identified using the
R package Haplotypes (R Foundation for Statistical Com-
puting). A detailed pipeline is reported in Figure S1.
AMP-PD Cohort Data
Clinical and sequencing data were downloaded from
the AMP-PD initiative website (https://amp-pd.org). Full
details on data collection can be found on the website.
Age at diagnosis, sex, and the GBA gene mutation calls
for cases diagnosed as “idiopathic PD” or “Parkinson’s
disease” in the AMP-PD cohort were downloaded on
July 20, 2020 (version 2019_v1release_1015).
Haplotype Definition
The full GBA gene sequence was analyzed for all par-
ticipants with PD from both the RAPSODI and AMP-
PD cohorts. Carriers of coding GBA variants were
excluded from the analysis. Each GBA allele was
assigned to one of two haplotypes.6 Haplotype A was
identified by alternate genotype at three intronic vari-
ants (rs9628662, rs762488, and rs2009578), whereas
haplotype B was identified by the reference genotype at
these variants. The minor allele population frequencies
in non-Finnish Europeans in the Genome Aggregation
Database (GnomAD) data (https://gnomad.
broadinstitute.org) are 0.295, 0.294, and 0.287, respec-
tively. Participants who carried at least one allele that
did not fall into this classification or for which quality
of the alignment at any of the three positions was not
good enough for confident calling were excluded from
the analysis.
Statistical Analysis
R version 4.0.2 was used for all statistical analyses.
To assess the effect of haplotypes on age at diagnosis of
PD, two models were investigated: an additive model
and a dominant model of haplotype B. For the additive
model, linear regression was used, with the number of
alleles carrying haplotype B as the dependent variable.
For the dominant model of haplotype B, participants
were divided into two groups according to whether
FIG. 1. Distribution of age at diagnosis of PD symptoms by GBA haplotypes. The boxes show the medians, and the hinges are the first and third quar-
tiles (25th and 75th percentiles): (a) RAPSODI cohort, (b) AMP-PD cohort, and (c) RAPSODI and AMP-PD cohorts together. RAPSODI, Remote Assess-
ment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease study;AMP-PD, Accelerating Medicines Partnership–
Parkinson’s Disease; Het, heterozygous; HomA, homozygous haplotype A; HomB, homozygous haplotype B; PD, Parkinson’s disease. [Color figure
can be viewed at wileyonlinelibrary.com]
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they carried at least one allele with haplotype B, and
ANOVA was used for the analysis.
Results
Participants and Genotypes
We analyzed 1417 patients, of whom 100 were rec-
ruited through RAPSODI, and the remainder were from
AMP-PD. More than 100 unique haplotypes were iden-
tified (Figure S2), and the overall allelic frequency of
each haplotype was 0.302 for haplotype A and 0.691
for haplotype B. The number of participants carrying
each haplotype, genotypes, and mean age at diagnosis
of PD are reported in Table 1. Of note, five (0.5%) par-
ticipants in the AMP-PD cohort carried at least one
allele that was not classifiable in either of the two hap-
lotypes, and were excluded from the analysis. More-
over, five samples in the RAPSODI cohort (5.0%) were
not classifiable into one of the two haplotypes. Upon
visual inspection of the sequencing data, the quality
was not adequate for unequivocal haplotype assign-
ment, and they were thus also excluded. Ethnic back-
grounds in the two cohorts are reported in Tables S1
and S2.
Haplotypes and Age at Diagnosis of PD
Mean and median age at diagnosis of PD are reported
in Table 1 and shown in Figure 1. After considering both
an additive model and a dominant effect of haplotype B
model, age at diagnosis of PD was not significantly dif-
ferent in the RAPSODI and AMP-PD cohorts separately.
There was also no significant difference after merging
the two cohorts together (P value > 0.3 for both the
additive model and dominant haplotype B model).
Because a significant number of participants with early-
onset PD (EOPD) can carry mutations in other PD-
causing genes,15 we repeated the analysis after removing
all participants with an age at diagnosis younger than 50.
Following this adjustment, there were 91 participants in
the RAPSODI cohort and 883 participants in the AMP-
PD cohort. Still, no significant effect of the two GBA hap-
lotypes on age at diagnosis of PD was observed. Data on
this additional analysis are reported in Table S1.
Discussion
In this article, we attempted to validate the recent report
that common haplotypes, identified by deep intronic vari-
ants in the GBA gene, could affect age at diagnosis of
PD.6 This hypothesis is intriguing as it could help explain
the reduced penetrance of GBA mutations and the role of
intronic variants in the pathogenesis of PD.
To this end, we analyzed our original cohort, gener-
ated through the RAPSODI portal, and the publicly
available AMP-PD cohort. We investigated both an
additive effect of the haplotypes and a dominant effect
of haplotype B, but did not observe any effect of haplo-
types on age at diagnosis of PD.
Both the RAPSODI and AMP-PD cohorts included
some participants who received a diagnosis of PD ear-
lier than age 50 and would thus be classified as EOPD.
Because a significant number of patients with EOPD
can carry variants in other PD-causing genes, we
repeated the analysis after excluding all patients with
EOPD. We still did not see any significant differences in
age of onset between the different haplotypes.
The RAPSODI and AMP-PD cohorts are similar in
their ethnic profiles. In RAPSODI, 96% of participants
identified themselves as “White UK,” and in the AMP-
PD cohort 93% of participants identified as “White.”
The remarkably similar minor allele frequencies in our
cohort to the European GNOMAD samples support this
ethnic classification. It is possible that the cohort studied
by Schierding et al.14 has a different balance of ethnic
backgrounds, which might explain in part the discrep-
ancy of results, although this information was not pro-
vided. Moreover, the inclusion of EOPD in the article by
Schierding et al. might have influenced the results.
One limitation of our study is that we could not
assess age at onset of PD symptoms, which had also
been reported as variable by haplotype, as this was not
captured in the RAPSODI and AMP-PD cohorts.
Our study does not exclude a possible role for
intronic variants. Although it is true that the majority
of alleles could be grouped into one of the two main
haplotypes according to their genotypes in three deep
intronic variants, more than 50 unique intronic haplo-
types were identified (Figure S2), and the role of each
single intronic variant in PD might extend beyond that
of these haplotypes and merits further study.
Conclusions
In this study, we were not able to confirm a role for
common GBA haplotypes in determining age at diagno-
sis of PD.
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